LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) and Vireo Growth (OTCMKTS:VREOD – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.
Risk and Volatility
LENZ Therapeutics has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Vireo Growth has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500.
Earnings and Valuation
This table compares LENZ Therapeutics and Vireo Growth”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| LENZ Therapeutics | $19.09 million | 5.02 | -$82.13 million | ($4.09) | -0.75 |
| Vireo Growth | $268.77 million | 1.68 | -$68.11 million | ($3.30) | -3.02 |
Vireo Growth has higher revenue and earnings than LENZ Therapeutics. Vireo Growth is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares LENZ Therapeutics and Vireo Growth’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| LENZ Therapeutics | -1,134.97% | -56.10% | -51.63% |
| Vireo Growth | -23.37% | -19.76% | -7.15% |
Institutional & Insider Ownership
54.3% of LENZ Therapeutics shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by insiders. Comparatively, 3.8% of Vireo Growth shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for LENZ Therapeutics and Vireo Growth, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LENZ Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
| Vireo Growth | 1 | 0 | 0 | 0 | 1.00 |
LENZ Therapeutics presently has a consensus price target of $17.50, suggesting a potential upside of 473.77%. Given LENZ Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe LENZ Therapeutics is more favorable than Vireo Growth.
About LENZ Therapeutics
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
About Vireo Growth
Goodness Growth Holdings, Inc. operates as a cannabis company in the United States. The company cultivates, processes, and distributes medical and adult-use cannabis products. It sells cannabis products through its network of Green Goods and other Goodness Growth branded retail dispensaries and third-party dispensaries in Maryland, Minnesota, and New York. The company was formerly known as Vireo Health International Inc. and changed its name to Goodness Growth Holdings, Inc. in June 2021. Goodness Growth Holdings, Inc. is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for LENZ Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENZ Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
